Blood-brain barrier delivery.

By W. Pardridge. Drug Discovery Today, 2007

1,131 citations recorded by the source corpus.

Subfields: Biomaterials, Oncology, Pediatrics, Perinatology and Child Health

View Paper: https://www.semanticscholar.org/paper/d7bc7050af0d2ea02754f86f726a7fe8f47efe70

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. R. Gabathuler
2. Berislav Zlokovic
3. Elif S. Seven
4. Zhili Peng
5. R. Leblanc
6. Yiqun Zhou
7. W. Pardridge

In Oncology

1. R. Gabathuler
2. Berislav Zlokovic
3. Behnam Noorani
4. L. Cucullo
5. Hossam Kadry
6. Elif S. Seven
7. Zhili Peng
8. R. Leblanc

In Pediatrics, Perinatology and Child Health

1. R. Gabathuler
2. Berislav Zlokovic
3. Behnam Noorani
4. L. Cucullo
5. Hossam Kadry
6. W. Pardridge

Citations in the corpus

• Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. (2010, methodology): “It has been reported that approximately 98% of the small molecules and nearly all large molecules (mw N 1 kD, kilodaltons), such as recombinant proteins or gene-based medicines do not cross the BBB (Pardridge, 1998, 2007c).”
• Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders (2011, background): “Some proteins, including transferrin, insulin, insulin-like growth factor 1 (IGF1), lepti”
• Drug Targeting to the Brain (2007, background): “mediation, which is >98% of all drugs (28), can cross the BBB via transport on one of many endogenous transporters.”
• The blood-brain barrier in health and chronic neurodegenerative disorders. (2008, neutral): “, recombinant peptides, proteins, anti-sense-agents and genetic vectors, are normally excluded from the brain (Pardridge, 2007).”
• A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity (2020, background): “More efforts need to be directed toward the development of BBB drug targeting technology using molecular Trojan horses as it seems to be a promising technique [148].”
• Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio (2015, background): “Penetrating the blood–brain barrier (BBB) and delivering anticancer drugs to the tumor at therapeutic levels is a major challenge in the treatment of brain cancers (14,26).”
• Crossing the blood‐brain barrier with nanoparticles (2018, background): “Another strategy, exploiting the abundant receptors expressed on the surface of endothelial cells of the barrier [116,117], focuses on the Fig.”